NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 124
- Registration Number
- NCT00232115
- Locations
- 🇩🇪
Novartis Pharmaceuticals, Nürnberg, Germany
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00231998
- Locations
- 🇯🇵
This study is not being conducted in the United States, Various Cities, Japan
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 160
- Registration Number
- NCT00232011
- Locations
- 🇯🇵
This study is not being conducted in the United States, Various Cities, Japan
Study of Omalizumab in Moderate to Severe Bronchial Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 327
- Registration Number
- NCT00232050
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 350
- Registration Number
- NCT00230074
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 212
- Registration Number
- NCT00228020
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00228059
- Locations
- 🇺🇸
Investigational Site, Cerritos, California, United States
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2008-02-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 652
- Registration Number
- NCT00226707
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 868
- Registration Number
- NCT00219232
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00219310
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath